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Patients with chronic hepatitis C and low serum and
hepatic iron stores may have an improved response to
interferon (IFN). We tested whether iron reduction before
and during IFN therapy would lead to an improved sus-
tained biochemical and virological response compared with
IFN alone. Eighty-two previously untreated patients with
chronic hepatitis C were randomized to either: group A
IFN-a2b 3 MU 3 times per week for 6 months, or group B
iron reduction before and during IFN-a2b 3 MU 3 times per
week for 6 months. Group B patients had lower mean serum
alanine transaminase (ALT) levels than group A patients
during treatment and follow-up. Group B patients had
significantly lower mean hepatitis C virus (HCV)-RNA
levels at treatment weeks 4 and 12 (P F .05). Serum HCV
RNA was undetectable at the end of treatment in 15 group B
patients compared with 7 group A patients (P 5 .03); 7
group B patients and 3 group A patients had persistently
undetectable serum HCV RNA 24 weeks after the end of
therapy (P 5 .20). Paired pre- and posttreatment liver
biopsies in 18 group B patients demonstrated significant
improvements in 2 of the 3 inflammation scores of the
Knodell histological activity index (P F .05). No changes
occurred in the paired biopsies from 15 group A patients.
We conclude that iron reduction via therapeutic phle-
botomy improves the end-of-treatment virological and histo-
logical response to short-term IFN therapy. Additional
studies are needed to determine if iron reduction in
combination with higher doses or longer duration of IFN
may be of benefit. (HEPATOLOGY 2000;31:730-736.)
Chronic hepatitis C is a leading cause of liver-related
morbidity and mortality in the United States and throughout
the world.1 Despite recent progress in treating chronic
hepatitis C with interferon (IFN) or IFN and ribavirin, most
North American patients still do not experience a sustained
virological response with these therapies. Furthermore, these
treatments are associated with unpleasant side effects leading
to dose reduction in as many as 26%, and early discontinua-
tion of therapy in as many as 21%, of treated patients.2-4
Improved and better-tolerated approaches to the manage-
ment of chronic hepatitis C are needed.
Lesser amounts of hepatic fibrosis, younger patient age,
female gender, infection with non–genotype 1 viral strains,
and lower levels of serum hepatitis C virus (HCV) RNA at
baseline are associated with an improved likelihood of
response to IFN.5 In addition, patients with lower levels of
serum ferritin, transferrin saturation, and hepatic iron have
been reported to have an improved response to IFN.6-10
Several studies have demonstrated that iron reduction via
therapeutic phlebotomy leads to improvements in serum
aminotransferase levels in patients with chronic hepatitis
C.11-14 In addition, iron reduction before IFN therapy in small
pilot studies has been shown to improve the response to IFN
in previous nonresponders with chronic hepatitis C.15,16 The
aim of this multicenter, randomized, controlled trial was to
determine if iron reduction before and during IFN therapy of
previously untreated patients with chronic hepatitis C would
lead to an improved biochemical and virological response
compared with IFN alone.
PATIENTS AND METHODS
Patient Population. Previously untreated patients with chronic
hepatitis C without histopathological evidence of bridging fibrosis
or cirrhosis were recruited for participation in this randomized,
controlled trial between October 1995 and June 1998. Subjects with
bridging fibrosis or cirrhosis at baseline were excluded because of
their known lower rates of response to IFN and greater likelihood of
having increased hepatic iron content, which could have biased the
results of the study.17-20 All subjects were adult ($18 years of age)
outpatients with detectable anti-HCV antibody and elevated serum
alanine transaminase (ALT) levels (.1.3 times the upper limit of
normal for .2 months). Other potential causes of chronic hepatitis
were uniformly excluded by reviewing the serum ceruloplasmin,
antinuclear antibody, smooth muscle antibody, antimitochondrial
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antibody, serum a1-antitrypsin, hepatitis B surface antigen, and
serum iron studies, as well as the liver biopsy. We also excluded
subjects with serious underlying medical conditions, contraindica-
tions to IFN therapy, human immunodeficiency virus infection,
active drug or alcohol use, evidence of leukopenia (,3,000/µL),
thrombocytopenia (,70,000/µL), anemia (hemoglobin ,12.0 g/dL),
or iron deficiency (baseline serum ferritin ,15 ng/mL or transferrin
saturation ,15%). Written informed consent was obtained from all
participants. The study protocol and consent forms were approved
by the Institutional Review Boards of the 7 participating centers
(University of Massachusetts, University of Michigan, Hartford
Hospital, Faulkner Hospital, SUNY Syracuse, Lahey Clinic, Mt. Sinai
Medical Center). Eighty-two subjects were entered into the trial.
Study Design and Treatment Regimens. Subjects were randomized to
receive either treatment A, IFN-a2b (Intron-A; Schering-Plough
Inc., Kenilworth, NJ) 3 MU 3 times per week for 6 months, or
treatment B, iron reduction before and during IFN-a2b 3 MU 3
times per week for 6 months. The randomization was performed at
UMass, the coordinating Center; a stratified randomization scheme
was used to assure that, for every 4 patients enrolled by each
participating center, 2 would be in treatment A and 2 in treatment B.
All subjects underwent standard laboratory and clinical monitoring
at treatment weeks 21, 0, 2, 4, 8, 12, 16, 20, 24, and during
posttherapy follow-up at weeks 4, 8, 12, and 24. Subjects with
persistently abnormal serum ALT levels and detectable HCV RNA
levels at treatment week 12 were classified as nonresponders and
were offered the opportunity to discontinue participation in this trial
so that they could pursue other treatment options.
Subjects randomized to treatment B underwent iron reduction via
therapeutic phlebotomy of 400 to 500 mL of whole blood using
standard techniques before and during IFN therapy. Initial phleboto-
mies were performed every 1 to 2 weeks until mild iron deficiency
anemia had developed, defined by 2 of the following 3 laboratory
criteria: prephlebotomy hematocrit ,35%, serum ferritin ,10
ng/mL, serum transferrin saturation ,10%. During IFN therapy,
additional phlebotomies were performed if the hematocrit exceeded
35% and either the serum ferritin exceeded 15 ng/mL or serum
transferrin saturation was greater than 15%.
Serum samples for quantitative HCV RNA were obtained at
enrollment, weeks 4, 12, and 24 of treatment, and week 24 of
follow-up. HCV RNA testing using quantitative reverse-transcrip-
tion polymerase chain reaction assay with a lower limit of detection
of 100 copies/mL (Superquantt) and HCV genotyping were per-
formed at a central reference laboratory (National Genetics Institute,
Culver City, CA).21,22 HFE gene mutational analysis of 27 patients
was performed at UMass using previously described methods.23
Study End-points. The primary end-point of this study was the
absence of detectable HCV RNA in serum 6 months’ posttreatment
(SVR). Secondary end-points of the study included the absence of
detectable HCV RNA at the end of therapy (ETVR), a biochemical
response at the end of treatment (ETBR), and a biochemical
response at the end of follow-up (SBR). A biochemical response was
defined as a decrease in serum ALT level into the normal range
(usually ,40 U/L).
Liver Biopsy. An adequate (.1.0 cm total length) pretreatment
liver biopsy obtained within 12 months of enrollment was required
of all subjects. Whenever possible, we also obtained posttreatment
biopsies at or near the end of treatment. Coded pretreatment (n 5
72) and posttreatment liver biopsies (n 5 33) were reviewed by a
single pathologist (B.F.B.) who was unaware of the treatment
assignment, clinical outcome, or sequence of the liver biopsies.
Posttreatment liver biopsies were obtained within 3 weeks of the
completion of therapy in most patients. Hepatic inflammation and
fibrosis were scored using the Knodell histological activity index
(HAI).24 Sections of liver tissue were also stained for iron. The
degree of iron staining was semiquantitatively graded using previ-
ously described methods.25 In addition, the percentage of portal
triads with iron-positive cells was determined.18
Measurements of Lipid Peroxidation. Lipid peroxidation was assessed
in 48 patients in whom concentrations of 8-epiprostaglandin F2a
(8EPGF2) and malondialdehyde in plasma samples were measured
at enrollment, weeks 4, 8, 12, and 24 of treatment, and weeks 4, 12,
and 24 of posttreatment follow-up. Measurements of 8EPGF2 were
made using an immunoassay kit following the manufacturer’s
instructions (Oxford Biomedical Research, Oxford, MI). Concentra-
tions of malondialdehyde were measured by a commercial colormet-
ric assay (Bioxytech LPO-586; Oxis International, Portland, OR).
Data Management and Statistical Analyses. Relevant data were re-
corded on appropriate forms. The forms were sent to UMass, where
the data were reviewed for accuracy, and a centralized database was
established. Initial analyses showed that results were distributed
normally. Therefore, parametric statistical procedures were used for
subsequent analyses (x2, Student t, paired t tests). All analyses were
performed on an intention-to-treat basis. To investigate correlations
between baseline characteristics and response to treatment, ANOVA
procedures were used, including both univariate and step-wise
multivariate regression analyses. Analyses were aided by SAS statisti-
cal software (SAS Institute, Cary, NC). P , .05 was considered
statistically significant.
RESULTS
The clinical, laboratory, and demographic features of the
patients in the 2 treatment groups at enrollment were comparable
(Table 1). However, by chance, black patients were more often
randomized to receive treatment A, while other nonwhite
patients were more often randomized to treatment B.
Serum HCV RNA Levels. The mean serum HCV RNA levels
decreased in both groups during treatment (Fig. 1). Subjects
receiving iron reduction 1 IFN had significantly lower mean
HCV RNA levels at treatment weeks 4 (0.81 3 106 6 0.25 vs.
1.71 3 106 6 0.37) and 12 (0.78 3 106 6 0.25 vs. 1.58 3 106 6
0.35) (P , .05). At the end of treatment, HCV RNA was
undetectable in 7 of the 41 patients who received treatment A
compared with 15 of the 40 patients who received treatment
B (P 5 .03) (Table 2). Among patients who had undetectable
HCV RNA at the end of treatment, the levels were already
undetectable at week 4 in 2 of 7 (28%) treatment A patients
compared with 11 of 15 (73%) treatment B patients (P 5 .029).
Serum HCV RNA remained undetectable at the end of
follow-up in 3 of the patients who had received treatment A
compared with 7 who had received treatment B (P 5 .20). In
patients with a sustained virological response, HCV RNA had
become undetectable at week 4 in 1 of 3 (33%) treatment A





Iron Red 1 IFN
(n 5 40) P*
Male (%) 26 (62%) 23 (58%) .69
White (%) 34 (81%) 33 (82%)
Black (%) 7 (17%) 1 (3%) .018
Other (%) 1 (2%) 6 (15%)
Age (yr) 43.0 6 1.26 42.6 6 1.17 .82
Serum ALT (U/L) 132 6 15 110 6 8.6 .20
Serum ferritin (ng/mL) 253 6 55 235 6 27 .77
Transferrin saturation (%) 33.6 6 2.12 34.6 6 2.3 .75
Serum HCV RNA
(cc/mL 3 1026) 2.7 6 0.33 2.9 6 0.31 .64
HCV genotype 1 (%) 32/40 (80%) 27/38 (71%) .21
*Two-tailed Fisher’s exact test for continuous variables; x2 for dichoto-
mous variables. Results are numbers of patients (%) or mean 6 SE.
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patients compared with 7 of 7 (100%) treatment B patients
(P 5 .054).
Serum ALT Levels. In all group B patients in whom data
were available (n 5 22), serum ALT levels decreased during
initial iron reduction before IFN therapy (Fig. 2). Patients
who received treatment B had consistently lower serum ALT
levels than those who received treatment A during treatment
and follow-up. Serum ALT levels were normal at the end of
treatment in 20 of the 42 patients treated with IFN alone and
25 of the 40 patients treated with iron reduction 1 IFN (P 5
.14). Serum ALT levels remained normal at the end of
follow-up in 6 of the patients who received IFN alone and 11
of the patients who received iron reduction 1 IFN (P 5 .14).
However, serum HCV RNA levels remained detectable after
treatment despite persistently normal serum ALT levels in 3
of the patients who received treatment A and 4 of the patients
who received treatment B. Similar discrepancies between the
sustained virological and biochemical responses have been
noted previously.26-28
Liver Histopathology. Liver histopathology before treatment
was available for review in 35 (83%) treatment A patients and
37 (92%) treatment B patients. The mean pretreatment total
HAI and inflammation scores were not significantly different
in the 2 groups (data not shown). However, the mean (6SE)
pretreatment fibrosis score was lower in group B patients
(0.9 6 0.1 fibrosis units) than in group A patients (1.5 6 0.2
fibrosis units) (P , .05). There were no appreciable differ-
ences before treatment in the presence or degree of stainable
iron in sinusoidal endothelial cells in lobular or portal areas
in the 2 treatment groups (data not shown). Posttreatment
liver biopsies were available in 15 (36%) group A patients and
18 (45%) group B patients. Paired comparisons of the pre-
and posttreatment biopsies revealed no significant change in
the total HAI scores or inflammation or fibrosis subscale
scores in the patients receiving IFN alone. In contrast,
significant decreases in 2 of the 3 inflammation subscale
scores (interface hepatitis and lobular hepatitis) were ob-
served in patients receiving treatment B, while the fibrosis
subscale and total HAI score remained unchanged (Table 3).
Serum Iron Studies. The mean baseline serum ferritin and
transferrin saturation levels were comparable in the 2 treat-
ment groups (Table 1). As expected, the mean pretreatment
serum ferritin levels were higher in men than in women (P 5
.012), but serum transferrin saturation levels were compa-
rable (P 5 .32). The mean number of phlebotomy sessions
(9.0 6 0.53 vs. 5.7 6 0.83; P 5 .001) and the mean volume of
blood removed (4.3 6 0.3 vs. 2.8 6 0.4 L; P 5 .003) to
achieve initial iron reduction were both greater in men
compared with women. In addition, men required a greater
number of phlebotomy sessions (1.6 vs. 0.6; P 5 .01) and
blood removal (0.7 6 0.1 vs. 0.3 6 0.1 L; P 5 .01) than
women to maintain a state of iron depletion during IFN
therapy.
Correlation of Pretreatment Characteristics With Response. We
tested the following clinical variables as univariate correlates
of SVR and SBR in all of the treated patients: gender, ethnic
background, HCV genotype, baseline serum ALT, ferritin,
transferrin saturation, HCV-RNA level, and total HAI score.
Only the pretreatment transferrin saturation level inversely
correlated with SVR (P 5 .03), while female gender showed a
trend toward a significant correlation with SBR (P 5 .07).
There were no significant correlations between ethnic back-
ground, HCV genotype, pretreatment serum ferritin, HCV-
RNA level, serum ALT, or total HAI score with either SVR or
FIG. 1. Time course of HCV-RNA levels. Patients receiving iron reduc-
tion 1 IFN (h) had significantly lower mean HCV-RNA levels at treatment
weeks 4 and 12 and at the end of posttreatment follow-up than patients
receiving IFN alone (d).Results expressed as mean 6 SE. *P # .05.
FIG. 2. Time course of serum ALT levels. Patients receiving iron
reduction 1 IFN (h) had lower mean serum ALT levels during treatment
and throughout posttreatment follow-up than patients receiving IFN alone
(d). Results expressed as mean 6 SE. *P # .05; **P # .01.






Iron Red 1 IFN
(n 5 40) P
Study completion
No. completing (%) 30 (71%) 28 (70%) .94
No. withdrawn (%) 12 (29%) 12 (30%) .90
End of treatment
Biochemical response (%) 20 (48%) 25 (62%) .14
Virological response (%) 7 (17%) 15 (37%) .03
End of follow-up
Biochemical response (%) 6 (14%) 11 (27%) .14
Virological response (%) 3 (7%) 7 (17%) .20
NOTE. Biochemical response was defined as serum ALT less than the
upper limit of normal (usually ,40 u/L); virological response was defined as
a lack of detectable HCV RNA (,100 cc/mL).
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SBR. In stepwise logistic regression analysis, only the baseline
serum transferrin saturation level was independently and
significantly inversely correlated with SVR in the entire group
of patients.
In group A patients, there was a significant correlation
between SBR and non-1 viral genotype (P 5 .04) and a trend
for women to achieve SBR more often than men (P 5 .07).
Among group B patients, there were significant inverse
correlations between SBR and baseline serum HCV RNA
levels (P 5 .009) and serum transferrin saturation levels (P 5
.046). In group B patients, an inverse correlation between
SVR was significant for baseline transferrin saturation (P 5
.01), and there was a trend toward inverse correlations with
baseline HCV RNA levels (P 5 .072) and HAI scores (P 5
.099). In group B patients, there was also a significant inverse
correlation between the total available body iron stores at
baseline and SVR (P 5 .02). The total available body iron
stores were estimated from the total amount of blood
removed to achieve initial iron reduction. Reanalysis of our
data omitting blacks, who according to recent results have
poorer response to IFN therapy, did not significantly change
the outcomes of the regression analyses (data not shown).5,29
Study Withdrawal. The same number of patients in each
treatment group (12 in A, 12 in B) withdrew from the study
prematurely. In 10 (77%) group A patients and 7 (58%) group
B patients, premature withdrawal was a result of nonresponse
at week 12. Other reasons for withdrawal included: moving
away (1 in B), noncompliance (1 in B), and other reasons (2
in A, 1 in B). Two subjects receiving treatment B developed
severe fatigue at weeks 1 and 8 of IFN therapy and were
withdrawn from the study. One subject originally randomized
to iron reduction 1 IFN had poor venous access precluding
phlebotomy and was treated with IFN alone.
HFE Mutations. Serum samples for HFE genotyping were
available in 27 patients (9 in group A and 18 in group B).
Eighteen of the tested patients demonstrated the wild-type
genotype at both the H63D and C282Y positions.30,31 Two
patients were heterozygous for the C282Y mutation, and 6
patients were heterozygous for the H63D mutation. A 37-year-
old white female was homozygous for the H63D mutation.
Her baseline serum ferritin level was 143 ng/mL, transferrin
saturation was 36%, and HCV genotype was 2b. There was
only trace iron staining in her pretreatment liver biopsy.
Despite the removal of 5.5 L of whole blood followed by IFN,
she did not experience a virological or biochemical response
and she withdrew from the study at week 12.
Lipid Peroxidation. There were no significant effects of
therapy on the plasma levels of 8EPGF2 or malondialdehyde
(data not shown).
DISCUSSION
IFN is recommended for chronic hepatitis C patients with
abnormal serum ALT levels and moderate hepatitis on liver
biopsy.32 In addition to hepatitis C viral genotype and hepatic
fibrosis, lower levels of serum ferritin, transferrin saturation,
and hepatic iron have been associated with an improved
response to IFN.5,10 In particular, the presence of stainable
iron in sinusoidal endothelial cells and/or portal tracts has
been correlated with a lower response to IFN.10,18-20 Elevated
serum ferritin and transferrin saturation levels have been
noted previously (and confirmed in this study) in 30% to 40%
of patients with chronic hepatitis C.10,33,34 Whether increased
serum or hepatic iron may potentiate the cytopathic effect of
hepatitis C via activation of iron-dependent lipid peroxida-
tion or alteration of immune-mediated responses in the liver
is unknown.10,35,36 Because serum ferritin levels correlate
with aminotransferase levels and the amount of hepatic iron
accumulation correlates with the degree of inflammation on
liver biopsy, hepatocytolysis with uptake of iron by hepatic
reticuloendothelial cells may be major sources of serum and
hepatic iron in chronic hepatitis C.7,10,33
Emerging evidence suggests that reduction of serum and
hepatic iron stores via therapeutic phlebotomy may lead to
improved biochemical and histological outcomes in patients
with chronic hepatitis C. Therapeutic phlebotomy in patients
with chronic hepatitis C consistently improves serum amino-
transferase levels and more recently has been shown to
improve liver histology.10-13,37 Phlebotomy before IFN therapy
has also been shown to improve the response to retreatment
with IFN in previous nonresponders.15,16 Therefore, we
hypothesized that iron reduction 1 IFN may lead to an
improved response in previously untreated patients with
chronic hepatitis C compared with IFN alone.
In this study, patients who received iron reduction 1 IFN
had consistently lower mean serum ALT levels during both
treatment and follow-up. In addition, patients receiving iron
reduction 1 IFN had lower mean serum HCV-RNA levels
during treatment and demonstrated a trend toward earlier
and improved sustained virological response compared with
patients receiving IFN alone. Paired comparison of pre- and
posttreatment liver biopsies revealed no significant change in
the total HAI or component scores in the patients treated with
IFN alone. However, significant decreases in 2 of the 3
component scores of inflammation were noted in the iron
reduction 1 IFN patients. Therefore, the results of this study
demonstrate that iron reduction 1 IFN is associated with
more frequent and rapid suppression of HCV RNA during
treatment and significant improvements in liver histology
compared with IFN alone. However, the improvements in
SBR and SVR with iron reduction 1 IFN failed to reach
statistical significance at the 5% level.
Stepwise multiple regression analysis demonstrated that
the only baseline clinical variable associated with a SVR in all
82 patients was the baseline transferrin saturation level (i.e.,
lower transferrin saturation levels were associated with
higher SVR). This variable was independent of gender even
though women had significantly lower pretreatment transfer-
rin saturation levels than men. In the 42 patients receiving














Pre Post Pre Post
Total 6.2 6 1.1 6.0 6 0.82 6.5 6 0.61 5.0 6 0.63
I 1.3 6 0.30 1.1 6 0.23 1.2 6 0.22 0.72 6 0.18
II 1.6 6 0.32 1.9 6 0.38 2.1 6 0.27 1.1 6 0.24*
III 2.1 6 0.34 1.9 6 0.29 2.4 6 0.26 1.7 6 0.23*
IV 1.2 6 0.31 1.2 6 0.26 0.83 6 0.71 1.4 6 0.29
NOTE. Results expressed as mean 6 SE. I 5 periportal 6 bridging
necrosis; II 5 lobular hepatitis; III 5 portal inflammation; IV 5 fibrosis.
*P , .05 comparing paired pre- and posttreatment scores.
HEPATOLOGY Vol. 31, No. 3, 2000 FONTANA ET AL. 733
IFN alone, women and those infected with non-1 HCV
genotypes were more likely to achieve an SBR as reported in
other studies.5 The lack of a clear association between HCV
genotype and SVR may be the result of the small number of
patients achieving viral eradication in both treatment groups.
In the 40 patients receiving iron reduction 1 IFN, SVR was
inversely correlated with baseline serum transferrin satura-
tion and the total available body iron stores. These findings
suggest that baseline serum and total body iron stores are
important predictors of response to IFN therapy, and that
patients with low serum and hepatic iron stores may particu-
larly benefit from iron reduction 1 IFN therapy.6-10 These
results may also help explain why women with chronic
hepatitis C, who have lower levels of iron at baseline, have
better responses to IFN than men.5
The patients entered into this multicenter, randomized,
controlled trial had comparable pretreatment clinical and
laboratory characteristics (Table 1). However, through the
vagaries of randomization, black patients and those with
higher pretreatment fibrosis scores were more likely to be
randomized to treatment A. Both of these factors have been
associated with a poorer response to IFN and may have
contributed to a lower sustained virological response in
group A patients compared with group B patients.5,29 How-
ever, at the time that this study was designed, there were no
data to suggest that blacks may have a poorer response to IFN
than whites. As a result, stratified randomization based on
ethnic background was not performed. In addition, in our
regression analyses, neither patient race nor baseline hepatic
histopathology was correlated with outcome regardless of the
treatment received. In addition, when we reanalyzed our data
omitting blacks, the results did not significantly change.
Higher doses or a longer duration of IFN therapy might
have led to an improved SVR in patients receiving iron
reduction 1 IFN. At the time that this study was designed
and initiated, however, IFN (3 MU 3 times per week for 6
months) was the recommended dose and duration of therapy
for previously untreated patients with chronic hepatitis C.
Since then, we have learned that a longer duration of IFN
(i.e., 12 vs. 6 months) is associated with a greater sustained
biochemical and virological response.32 In addition, other
recent studies suggest that higher doses of IFN, as well as
daily administration of IFN, lead to a more rapid suppression
of HCV RNA levels than standard doses of IFN.38 In one study
of previous nonresponders to IFN alone, iron reduction
before and during retreatment with high doses of daily IFN (5
MU per day for 6 months) led to a SVR of 6 of 15 (40%)
compared with 2 of 15 patients (13%) retreated with 5 MU
per day for 6 months without iron reduction.15 Therefore, a
greater benefit from iron reduction 1 IFN might have been
achieved if higher doses or a longer duration of IFN had been
used.
Another study, similar in design to ours, comparing the
potential benefit of iron reduction 1 short-term IFN with
IFN alone in 38 previously untreated patients was recently
reported by Fong et al.39 The 17 patients treated with iron
reduction 1 IFN demonstrated a trend toward improved SVR
compared with the 21 patients receiving IFN alone (29% vs.
5%; P 5 .07). Another study from Italy also demonstrated an
improved response to iron reduction 1 IFN compared with
IFN alone in 103 patients with noncirrhotic chronic hepatitis
C.40 The similar results obtained in these 3 studies suggest
that iron reduction 1 IFN may be superior to IFN alone, but a
larger sample size may be needed to demonstrate a statisti-
cally significant difference. Other recent data also suggest that
long-term maintenance of hepatic iron reduction via therapeu-
tic phlebotomy in chronic hepatitis C decreases the incidence
of hepatic decompensation and hepatocellular carcinoma.37
Thus, iron reduction may be beneficial in hepatitis C even
though it does not lead to viral eradication.
Therapeutic phlebotomy before and during IFN was well
tolerated in our study, with only 2 (5%) patients reporting
adverse events that required early discontinuation. The
overall adverse-event rate was comparable in the 2 treatment
groups. The low number of therapeutic phlebotomy sessions
required to achieve mild iron deficiency anemia suggests that
the increase in hepatic iron content in these noncirrhotic
patients with hepatitis C was absent or mild as previously
reported.41 Semiquantitative analysis of the lobular and portal
distribution of iron in pretreatment liver biopsies also demon-
strated low hepatic iron levels (data not shown). Although
serum ferritin and transferrin saturation levels were elevated
in 33% and 20%, respectively, of study subjects before
treatment, HFE mutational analysis demonstrated that none
of the 27 subjects tested had a genotype associated with the
genetic hemochromatosis phenotype (C282Y homozygote or
compound heterozygote, C282Y/H63D). The frequencies of
heterozygosity for the C282Y and H63D mutations observed
in our patients were comparable with those reported in other
studies of patients with chronic hepatitis C, other forms of
chronic liver disease, and normal controls.30,31,42,43 One
patient was homozygous for the H63D mutation, but her
hepatic iron content was not increased. It remains unclear if
H63D homozygotes are at risk of developing phenotypic
hemochromatosis.30,31
No significant differences in the plasma levels of lipid
peroxidation markers were noted during treatment or fol-
low-up in the 2 treatment groups (data not shown). Although
we are uncertain as to the reasons for a lack of an effect of
treatment on measures of lipid peroxidation, it is possible
that the assays used were insufficiently sensitive and precise
to detect changes caused by iron reduction and/or IFN. In
addition, it is possible that the increases caused by chronic
hepatitis C may have overshadowed the effects of the
therapies used.35,36
In summary, our results demonstrate that iron reduction
before and during IFN therapy is well tolerated and associ-
ated with greater improvements in end-of-treatment virologi-
cal and histological response rates than IFN alone. However,
perhaps as a result of the limited number of patients enrolled
and the low doses and short duration of IFN therapy used, the
SVR and SBR with iron reduction 1 IFN was not significantly
greater than that seen with IFN alone. Nonetheless, this study
and others suggest a role for iron as a comorbid factor in
mediating liver injury in chronic hepatitis C.28,39,40 We
conclude that iron reduction 1 IFN is a safe and potentially
promising means of treating patients with chronic hepatitis
C. However, large, randomized, controlled trials using iron
reduction with higher doses or longer duration of IFN
therapy will be needed before iron reduction 1 IFN can be
recommended as an established means of treating patients
with chronc hepatitis C. When newer approaches to manage-
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ment of chronic hepatitis C are developed (e.g., helicase or
RNA polymerase inhibitors), it may be worthwhile assessing
iron reduction as an adjunctive therapy.
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